On Monday, Best Buy Co Inc (NYSE:BBY)’s shares declined -0.09% to $34.92.
Best Buy Co Inc (BBY)’s Geek Squad declared the launch of the ninth Geek Squad Academy summer program. This grassroots tech experience inspires under-served teens to consider technology careers and assist address the nation’s widely-anticipated professional labor shortage.
According to the Change the Equation, a group of Fortune 500 companies that encourages students to pursue STEM (science, technology, engineering and math) careers, the American workforce is still failing to pursue different fields. The lack of broad representation in these high-demand areas threatens the U.S. economy by creating a competitive advantage for other countries.
Conducted in partnership with non-profit organizations such as the Boys & Girls Clubs of America, Junior Achievement and Young Adult Library Services Association, Geek Squad Academy classes are designed by Geek Squad Agents to demystify technology and ignite a passion for technology through fun and inspiring hands-on learning. At this year’s sessions, students will explore the ins and outs of technology through subjects like digital citizenship, film production, computer programming and robotics, in addition to 3D printing and circuitry.
Best Buy Co., Inc. operates as a retailer of technology products, services, and solutions in the United States and internationally. Its stores offer consumer electronics comprising primarily of television and home theaters; digital cameras and camcorders; DVD and Blu-ray players; portable electronics, such as MP3 devices, headphones and speakers, car stereo, navigation and satellite radio; and related accessories.
Public Service Enterprise Group Inc. (NYSE:PEG)’s shares dropped -0.66% to $40.72.
Public Service Enterprise Group Inc. (PEG) through its wholly-owned subsidiary PSEG Fossil, has acquired the 755-MW Keys Energy Center project from Genesis Power, LLC and an energy-focused private equity fund managed by Ares EIF Management, LLC. PSEG Power plans to rename the facility the PSEG Keys Energy Center (KEC).
PSEG Power – an independent power producer and partner of PSEG – anticipates to start construction of the natural gas-fired, combined-cycle plant in 2015. The plant, which represents an investment of $825 - $875 million, is targeted to be accomplished and supplying needed capacity and energy to the state of Maryland and region in 2018. The project was bid into and cleared the PJM capacity auction in May 2014.
PSEG Fossil will oversee construction, operate and maintain the combined-cycle plant. SNC - Lavalin Constructors Inc. is the designated engineering, procurement and construction contractor. The combined-cycle plant will use state-of-the-art generating technology, counting a full complement of emissions controls and run on clean, efficient natural gas. The plant will generate about 700 jobs during the two-year construction phase. More than 20 permanent jobs will be created to run the new plant once it becomes operational.
Public Service Enterprise Group Incorporated, through its auxiliaries, operates as an energy company primarily in the northeastern and Mid Atlantic United States. The company operates nuclear, coal, gas, oil-fired, and renewable generation facilities with a generation capacity of about 13,146 megawatts. It sells electricity, natural gas, emissions credits, and a series of energy-related products that are used to optimize the operation of the energy grid.
At the end of Mondays trade, CEL-SCI Corporation (NYSEMKT:CVM)‘s shares dipped -0.15% to $0.659.
CEL-SCI Corporation (NYSE MKT: CVM) (“CEL SCI” or the “Company”) recently declared that CEL-SCI is now cleared to start patient enrollment in Thailand in its ongoing Phase 3 trial with its investigational cancer immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary (not yet treated) head and neck cancer. Thailand is the 24th country to authorize CEL-SCI’s Phase 3 trial for patient enrollment.
“We have now accomplished enrollment of over 50% of the anticipated 880 patients in our Phase 3 trial and continue to expand the trial into more sites to enhance the rate of enrollment. In the past month alone, we have added Spain and Italy as participating countries in our trial. We plan to have about 100 clinical centers around the world in about 25 countries screening and treating patients,” stated CEL-SCI Chief Executive Officer Geert Kersten.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. The companys lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. Multikine is also being used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System (LEAPS), a patented T-cell modulation process, stimulates the human immune system to fight bacterial, viral, and parasitic infections, in addition to autoimmune, allergies, transplantation rejection, and cancer.
Juno Therapeutics Inc (NASDAQ:JUNO), ended its Monday’s trading session with 1.19% gain, and closed at $51.72.
Juno Therapeutics Inc (JUNO) might not be turning a profit yet, but that’s no problem for CEO Hans Bishop’s personal bottom line.
Bishop is the 11th highest-paid CEO in the country, according to Bloomberg’s Pay Index, a daily ranking of the 100 top-paid executives. His pay package was worth $88.2 million at the end of 2014, Bloomberg stated Thursday, in a combination of salary, stock options and restricted shares. That was worth $7.3 million before Juno’s initial public offering in December.
Juno isn’t the only biotech to show up near the top of the list. CEO pay at Santa Monica, Calif.-based Kite Pharma and Waltham, Mass.-based Radius Health Inc. topped $95 million and $33.5 million, respectively.
Juno and Kite develop immunotherapy treatments for cancer. That’s a field investors have been excited to jump into in recent years. Immunotherapy reprograms a patient’s T cells and then infuses them back into the body, giving the immune system a boost to battle the cancer.
This treatment has been heralded in recent years as a breakthrough alternative to harsher methods, such as chemotherapy and radiation.
In small clinical trials, one of Juno’s drug candidates has achieved a 90 percent remission rate in a type of blood cancer.
Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
